Literature DB >> 16983123

Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.

David M Jackman1, Alison J Holmes, Neal Lindeman, Patrick Y Wen, Santosh Kesari, Ana M Borras, Christopher Bailey, Francisca de Jong, Pasi A Jänne, Bruce E Johnson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16983123     DOI： 10.1200/JCO.2006.06.6126

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  94 in total

1.  DHPLC/SURVEYOR nuclease: a sensitive, rapid and affordable method to analyze BRCA1 and BRCA2 mutations in breast cancer families.

Authors:  Brunella Pilato; Simona De Summa; Katia Danza; Stavros Papadimitriou; Paolo Zaccagna; Angelo Paradiso; Stefania Tommasi
Journal:  Mol Biotechnol       Date:  2012-09       Impact factor: 2.695

Review 2.  Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature.

Authors:  Megan O Jacus; Vinay M Daryani; K Elaine Harstead; Yogesh T Patel; Stacy L Throm; Clinton F Stewart
Journal:  Clin Pharmacokinet       Date:  2016-03       Impact factor: 6.447

3.  Long-lasting response to crizotinib in brain metastases due to EML4-ALK-rearranged non-small-cell lung cancer.

Authors:  Yoshiaki Kinoshita; Yasutaka Koga; Atsuhiko Sakamoto; Kouko Hidaka
Journal:  BMJ Case Rep       Date:  2013-09-10

4.  Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.

Authors:  Stephanie Heon; Beow Y Yeap; Gregory J Britt; Daniel B Costa; Michael S Rabin; David M Jackman; Bruce E Johnson
Journal:  Clin Cancer Res       Date:  2010-10-28       Impact factor: 12.531

Review 5.  Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future.

Authors:  Claudia Proto; Martina Imbimbo; Rosaria Gallucci; Angela Brissa; Diego Signorelli; Milena Vitali; Marianna Macerelli; Giulia Corrao; Monica Ganzinelli; Francesca Gabriella Greco; Marina Chiara Garassino; Giuseppe Lo Russo
Journal:  Transl Lung Cancer Res       Date:  2016-12

Review 6.  Non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases: role of tyrosine kinase inhibitors (TKIs) and evidence in favor or against their use with concurrent cranial radiotherapy.

Authors:  Panagiota Economopoulou; Giannis Mountzios
Journal:  Transl Lung Cancer Res       Date:  2016-12

Review 7.  Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors.

Authors:  Grainne M O'Kane; Natasha B Leighl
Journal:  CNS Drugs       Date:  2018-06       Impact factor: 5.749

Review 8.  Long Term Therapeutic Plan for Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutation.

Authors:  Seung Hun Jang
Journal:  Tuberc Respir Dis (Seoul)       Date:  2014-01-29

9.  Gefitinib and high-dose fractionated radiotherapy for carcinomatous encephalitis from non-small cell lung carcinoma.

Authors:  Eric T Wong; Julian K Wu; Anand Mahadevan
Journal:  Biologics       Date:  2007-09

10.  Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.

Authors:  Andrew J Weickhardt; Benjamin Scheier; Joseph Malachy Burke; Gregory Gan; Xian Lu; Paul A Bunn; Dara L Aisner; Laurie E Gaspar; Brian D Kavanagh; Robert C Doebele; D Ross Camidge
Journal:  J Thorac Oncol       Date:  2012-12       Impact factor: 15.609
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.